Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT
Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best gene-editing stocks to buy according to hedge funds.
Krystal Biotech Inc. (KRYS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,777,777 | $490,360,974 | +5% | 6.34% |
| 2. | Soleus Capital Guy Levy | 1,018,831 | $179,854,236 | +11% | 9.05% |
| 3. | Redmile Group Jeremy Green | 661,388 | $116,754,824 | -1% | 11.36% |
| 4. | Citadel Investment Group Ken Griffin | 636,988 | $112,447,492 | +1744% | 0.02% |
| 5. | Hood River Capital Management David Swank | 606,946 | $107,144,177 | +14% | 1.27% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 25,000 | $500,000.00 | 2,001,462 | 2018-10-18 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 2,036,462 | 2018-10-18 | Filing | |
| $12.45 | 1,018 | $12,674.10 | 1,976,462 | 2018-06-06 | Filing | |
| $11.15 | 13,116 | $146,177.82 | 1,975,444 | 2018-06-06 | Filing | |
| $10.75 | 10,866 | $116,757.34 | 1,962,328 | 2018-06-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $222.20 | 700 | $155,539.02 | 1,483,056 | 2025-12-04 | Filing | |
| $221.78 | 10,505 | $2,329,771.59 | 1,483,756 | 2025-12-04 | Filing | |
| $220.34 | 2,625 | $578,394.60 | 1,494,261 | 2025-12-04 | Filing | |
| $219.53 | 5,693 | $1,249,803.08 | 1,496,886 | 2025-12-04 | Filing | |
| $218.72 | 2,577 | $563,637.83 | 1,502,579 | 2025-12-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,341,447 | $766,395,653 | 0.04% | |
| 2. | 3,834,128 | $676,838,615 | 0.01% | |
| 3. | 2,792,208 | $492,908,477 | 0.01% | |
| 4. | 1,395,967 | $246,430,055 | 0.01% | |
| 5. | 809,240 | $142,855,137 | 0.02% |
News See All
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Krystal Biotech Third Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded.
TSCM U.S. Small Cap Growth Strategy Reduced Its Position in Krystal Biotech (KRYS)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2025 investor letter.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Krystal Biotech Q2 2025 Earnings Call. [Operator Instructions] As a reminder, today's conference is being recorded.
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2025 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Krystal Biotech First Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2024 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to the Krystal Biotech Q4 2024 Earnings Call. At this time, all participants are on a listen-only mode.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by and welcome to Krystal Biotech's Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.
10 Worst Booming Stocks to Buy According to Short Sellers
September has historically been one of the worst months for US stocks.
Hedge Fund Resource Center Billionaire Hedge Funds
